Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen independent LNCaP AI prostate cancer cells
Sphingosine kinases (two isoforms termed SK1 and SK2) catalyse the formation of the bioactive lipid sphingosine 1 phosphate. We demonstrate here that the SK2 inhibitor, ABC294640 (3 (4 chlorophenyl) adamantane 1 carboxylic acid (pyridin 4 ylmethyl)amide) or the SK1/SK2 inhibitor, SKi (2 (p hydroxyanilino) 4 (p chlorophenyl)thiazole) induce the proteasomal degradation of SK1a (Mr 42 kDa) and inhibit DNA synthesis in androgen independent LNCaP AI prostate cancer cells. These effects are recapitulated by the dihydroceramide desaturase (Des1) inhibitor, fenretinide. Moreover, SKi or ABC294640 reduce Des1 activity in Jurkat cells and ABC294640 induces the proteasomal degradation of Des1 (Mr 38 kDa) in LNCaP AI prostate cancer cells. Furthermore, SKi or ABC294640 or fenretinide increase the expression of the senescence markers, p53 and p21 in LNCaP AI prostate cancer cells. The siRNA knockdown of SK1 or SK2 failed to increase p53 and p21 expression, but the former did reduce DNA synthesis in LNCaP AI prostate cancer cells. Moreover, N acetylcysteine (reactive oxygen species scavenger) blocked the SK inhibitor induced increase in p21 and p53 expression but had no effect on the proteasomal degradation of SK1a. In addition, siRNA knockdown of Des1 increased p53 expression while a combination of Des1/SK1 siRNA increased the expression of p21. Therefore, Des1 and SK1 participate in regulating LNCaP AI prostate cancer cell growth and this involves p53/p21 dependent and independent pathways. Therefore, we propose targeting androgen independent prostate cancer cells with compounds that affect Des1/SK1 to modulate both de novo and sphingolipid rheostat pathways in order to induce growth arrest.
Oncotarget